Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment

Mattia Siciliano1,2,3, Rosa De Micco1, Andrea Gerardo Russo1

  • 1Department of Advanced Medical and Surgical Sciences-MRI Research Center Vanvitelli-FISM, University of Campania "Luigi Vanvitelli", Naples, Italy.

Abstract

Insights

Parkinson's disease with mild cognitive impairment (PD-MCI) presents diverse memory issues. This study identified three distinct memory phenotypes in early PD-MCI patients, aiding in understanding and treatment.

Area of Science:

  • Neurology
  • Neuroscience
  • Cognitive Science

Background:

  • Memory deficits in Parkinson's disease with mild cognitive impairment (PD-MCI) are highly variable.
  • The underlying causes of these heterogeneous memory impairments remain unclear.

Purpose of the Study:

  • To characterize memory phenotypes in de novo PD-MCI patients.
  • To investigate associations between memory phenotypes and motor/non-motor features.
  • To examine the impact of memory phenotypes on patients' quality of life.

Main Methods:

  • Cluster analysis of memory function in 82 de novo PD-MCI patients.
  • Comparison with 101 cognitively unimpaired individuals.
  • Utilized cognitive measures and structural MRI for neural correlates.

Main Results:

  • Identified three memory phenotypes: unimpaired, mild episodic memory disorder (prefrontal executive-dependent), and severe episodic memory disorder (hybrid phenotype).
  • Progressive increase in attention/executive deficits across phenotypes.
  • The severe memory disorder group reported worse quality of life.

Conclusions:

  • De novo PD-MCI exhibits significant memory heterogeneity, manifesting as three distinct phenotypes.
  • Phenotype identification is crucial for understanding PD-MCI pathophysiology and subtypes.
  • Findings can guide the development of targeted therapeutic strategies for PD-MCI.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
143
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223